Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT.

Of note, a clear trend of tumor growth inhibition was observed even with the low dose of [ 67 Cu]Cu-NOTA-Pertuzumab in Group 2 , in which the tumor size remained almost the same out to 25 days.

also in 19,460 other papers